
Opinion|Videos|January 28, 2025
Overview of the POLARIX Study
Panelists discuss the findings from the POLARIX study, focusing on the efficacy and safety of polatuzumab vedotin in combination with rituximab and chemotherapy for untreated diffuse large B-cell lymphoma.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5


















